Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Infectious Disease
•
Tuberculosis
•
Pulmonology
•
Pulmonary Infections
Do you routinely monitor imaging or pulmonary function in patients with pulmonary TB after the completion of therapy?
Answer from: at Community Practice
The simple answer will be: NO.
Sign in or Register to read more
17975
Related Questions
Are there clinical scenarios in which you would start empiric treatment for pulmonary TB without microbiologic confirmation?
Does your institution have formal policies or work flows to reduce unnecessary IGRAs ordered for patients on biologics?
How would you approach treatment of latent TB for patients who cannot tolerate rifamycins or isoniazid due to allergy, intolerance, or drug-drug interactions?
What is the interpretation of two IGRAs with negative mitogen wells, in the absence of immunosuppression?
What is the interpretation of an IGRA with positive TB wells and negative nil and negative mitogen wells?
Would you use the pneumococcal conjugate-21 vaccine (Capvaxive) instead of the conjugate-20 (Prevnar-20) for routine vaccinations in immunosuppressed patients?
Have you incorporated the use of steroids for patients with severe community-acquired pneumonia?
Would you start treatment for MAC in a patient with nodular bronchiectatic disease who has demonstrated radiographic progression but remains asymptomatic and smear-negative?
How would you treat an asymptomatic patient with a positive Blastomyces antibody, evidence of prior granulomatous lung disease on imaging, and who may require immunosuppression in the future?
Is there any utility to trending Histoplasma serology titers to guide duration of therapy or treatment response for pulmonary histoplasmosis with negative urine antigen?